CAR T-Cell Immunotherapy in Minority Patients with Lymphoma-Reference-Cited by-同舟云学术

CAR T-Cell Immunotherapy in Minority Patients with Lymphoma

Published:2024-03-26 Issue:4 Volume:3 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Ghilardi Guido¹²³,Williamson Staci⁴,Pajarillo Raymone¹²³,Paruzzo Luca¹²³,Chen Linhui¹²³,Grady Connor⁵,Doucette Abigail⁶,Nemecek Eneida⁴,Gabrielli Giulia¹²³,Barta Stefan K.¹³,Svoboda Jakub¹³,Chong Elise A.¹³,Yelton Rebecca¹²³,Nasta Sunita D.¹³,Landsburg Daniel J.¹³,Ugwuanyi Ositadimma¹²³,Chen Andy I.⁴,Schachter Levanto⁴,White Griffin¹³,Ballard Hatcher J.¹³,Weber Elizabeth¹³,Curley Cara⁶,Porter David L.¹²,Garfall Alfred L.¹²,Hwang Wei-Ting⁵,Guerra Carmen E.⁷,Maziarz Richard T.⁴,Schuster Stephen J.¹²³,Ruella Marco¹²³

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia

2. Center for Cellular Immunotherapies and Cellular Therapy and Transplant, University of Pennsylvania, Philadelphia

3. Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia

4. Adult Blood and Marrow Stem Cell Transplant and Cell Therapy Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR

5. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

6. Division of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia

7. Division of General Medicine, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia

Publisher

Massachusetts Medical Society

Reference36 articles.

1. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

4. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

5. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Assessment of CAR-T Cell Therapy Utilization among Racial and Ethnic Minority Patients;NEJM Evidence;2024-03-26

2. Delivery of Novel Therapies without Ensuring Equitable Access — Are Cancer Centers Putting the CART19 before the Horse?;NEJM Evidence;2024-03-26